Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237053 · ClinicalTrials.gov registry record · Phase 1
Effects of Glucagon Administration on Energy Expenditure
A Phase 1 study of Obesity and Hyperglucagonemia, sponsored by AdventHealth Translational Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02237053: Completed Phase 1 study of Obesity and Hyperglucagonemia, sponsored by AdventHealth Translational Research Institute.
NCT02237053 is a Phase 1 study of Obesity and Hyperglucagonemia that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 6 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02237053, a Phase 1 study of Obesity and Hyperglucagonemia, has completed, sponsored by AdventHealth Translational Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
Primary Outcome
Energy expenditure (and respiratory quotient) will be measured within the small calorimeter rooms. Oxygen and carbon dioxide levels in the chambers will be measured.
Conditions Studied
Interventions
- DRUG Insulin
- BEHAVIORAL Placebo
- DRUG Glucagon
- DRUG Octreotide
Study Locations (1)
Florida
- Florida Hospital Translational Research Institute for Metabolism and Diabetes - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
What the finished NCT02237053 record still lists
NCT02237053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Insulin is the first listed.
NCT02237053 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02237053 about?
NCT02237053 is a clinical study titled "Effects of Glucagon Administration on Energy Expenditure". The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
What is the current status of trial NCT02237053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-09. Estimated completion is 2016-06.
What conditions does trial NCT02237053 study?
This clinical trial studies the following conditions: Obesity, Hyperglucagonemia.
What interventions are being tested in trial NCT02237053?
The interventions under investigation include: Insulin (DRUG), Placebo (BEHAVIORAL), Glucagon (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT02237053?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02237053 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02237053's enrollment target sits among peer trials
6 1048th of 1053 higher than 5 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia